Introduction

We are committed to delivering innovative therapies to our patients throughout the world. We believe in the need for innovative clinical research to be conducted, which addresses important medical and scientific questions for our therapeutic areas of interest.

smiling-woman-with-shaved-head

How we use our research for our therapies

An IIR is an unsolicited request for funding and/or material support (e.g., drug product) from an external investigator to conduct an independent scientific investigation. An IIR is conceived, designed, initiated, conducted, analysed, and reported by a qualified Investigator who is not an employee, contractor, or agent of Britannia Pharmaceuticals Ltd. and has the scientific background and experience to conduct an independent scientific investigation. To see our therapeutic areas of interest, please see our therapies section.

close-up-of-pipette

Participating

Only institutions/organisations are eligible to receive IIR support from BPL – not individuals. Healthcare Professionals (HCPs) serving as primary investigators or co-investigators and their respective institutions will be screened for potential debarment and other exclusions.

Our Process

Stages Application Process Britannia Pharmaceuticals
Stages 1 Application Process Investigator submits IIR Concept proposal to Britannia Pharmaceuticals Ltd. Britannia Pharmaceuticals Review of summary of concept
Communication of decision to decline or request study outline
Stages 2 Application Process Investigator Initiated Research Project Manager notifies investigator of suitability of application. Britannia Pharmaceuticals Review of study outline
Initiate fair market value review
Communication of decision to decline or request protocol
Stages 3 Application Process Investigator submits further documentation with full protocol. Britannia Pharmaceuticals Review of protocol
Communication of decision to decline or initiate research agreement activities
Stages 4 Application Process Investigator is informed of decision once reviewed by Britannia Pharmaceuticals Ltd.